💥 Gate Square Event: #PostToWinCC 💥
Post original content on Gate Square related to Canton Network (CC) or its ongoing campaigns for a chance to share 3,334 CC rewards!
📅 Event Period:
Nov 10, 2025, 10:00 – Nov 17, 2025, 16:00 (UTC)
📌 Related Campaigns:
Launchpool: https://www.gate.com/announcements/article/48098
CandyDrop: https://www.gate.com/announcements/article/48092
Earn: https://www.gate.com/announcements/article/48119
📌 How to Participate:
1️⃣ Post original content about Canton (CC) or its campaigns on Gate Square.
2️⃣ Content must be at least 80 words.
3️⃣ Add the hashtag #PostTo
Anglikan: The only innovative drug project currently under research is ALK-N001.
Golden Ten Data on June 9, Anglikang issued a change announcement, the company’s shares for 2 consecutive trading days closing price deviation of more than 20%, belongs to the abnormal fluctuation of stock trading. The company’s current innovative drug project under development is only ALK-N001, which obtained the drug clinical trial approval notice in April 2025 and is still in the phase I clinical trial stage as of the disclosure date of this announcement. The R&D of innovative drugs has the characteristics of long cycle, large investment and high uncertainty, so investors should pay attention to investment risks.